In line with this study, CB-839, a GLS inhibitor, has anti-proliferative activity in triple-negative breast cancer and basal-like HER2-positive breast cancer, but not in luminal type estrogen receptor-positive T47D cells [13]. Here, ERBB2 is linked to breast carcinoma.